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Abstract
In this interview, we talk to leading tuberculosis (TB) experts from University College London and the London
School of Hygiene and Tropical Medicine about the current challenges in TB research. The video of this interview is
available here: https://www.youtube.com/watch?v=75Die7MQBec&feature=youtu.be. The video can also be
downloaded via Additional file 1.
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Introduction
Patrick Phillips (PPJP)
Tuberculosis (TB) is the leading infectious disease killer
at the moment. The recent surveillance reports have
showed that more people die from TB every year than
from HIV or any other infectious disease. So it’s critically
important that we tackle TB.
Helen Fletcher (HF)
Whereas people know about HIV and malaria, less
people know about TB. In some ways, it is a silent
pathogen. It is there in the community, it causes huge
amounts of health problems, huge amounts of morbid-
ity, and yet we have really under-invested in and
neglected this disease as a global health problem.
Ibrahim Abubakar (IA)
If we are to contain the global burden of TB, we need
new tools and diagnostics as well as new treatments and
a vaccine. In order to achieve this, researchers have a
key role to play.
The re-emergence of TB
HF
TB has always been there. We’ve never been close to
eradication.
PPJP
In Western Europe, we’ve seen something of a decline in
TB over the years, but TB is still a problem in many
parts of the world. There has been a particular increase
in the last 10–20 years or so due to a number of factors.
The emergence of the HIV epidemic – HIV knocks out
a person’s immune system and makes them much more
susceptible to TB – but also we have seen increasing
rates of drug resistance.
Marc Lipman (MCIL)
We also know that social cohesion in a society is incred-
ibly important in reducing the rates of TB. This is asso-
ciated with poverty and, therefore, often in parts of the
world where there is civil conflict, rates of TB, as well as
those for other infections, start to rise. This extremely
important in terms of where TB went to – or more im-
portantly – why it has not gone away.
TB transmission
IA
TB is an infectious disease acquired from person to per-
son. It is fundamental to the control of TB that we under-
stand transmission, because if we can stop transmission
then we have a chance in ultimately eliminating TB, as is
the case with the goal of the End TB Strategy. It is there-
fore of interest to me that we use the best technology
available, whether that is whole genome sequencing, geo-
graphical mapping of cases, tools to identify clusters of
cases, as well as computer programs that predict where
transmission is happening, and improved statistical
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approaches to pinning down exactly where transmission is
happening. Those are the key steps we require.
Increasingly, we are recognising that transmission does
not necessarily happen in peoples’ households; that a lot
of transmission, especially in high burden settings, actually
happens out there in indoor-congregate community set-
tings. Therefore, knowing exactly where these congregate
settings are, and putting in interventions to stop transmis-
sion in those settings, is the key to containing TB.
Drug resistance
MCIL
Although we are definitely seeing an improvement in
outcomes in terms of TB, we are also starting to see is-
sues such as drug resistance. That is a direct conse-
quence of treatment regimens that have been ineffective.
Timothy McHugh (TMcH)
There are two aspects to why drug resistance emerges.
The first is wholly about the patient and the relationship
between the patient and the clinician. So it is the drugs
that are given and whether the patient has been given
drugs that are going to work, and whether they are the
right drugs, and then whether the patient is able to take
those in the way that we require them to. It might be
that the drugs make them feel ill, so they don’t want to
take them. Or it might be that the patient is leading a
chaotic lifestyle and so isn’t able to take the drugs on a
regular basis. That is what my clinician colleagues focus
on – they have to manage that process.
What I’m interested in, and what my team look at, is the
evolution of drug resistance – or how it emerges at a bio-
logical level for the bug itself. For me it is a question of, al-
most, compartments. TB is tucked away within the host,
within the patient. It is a difficult site to get drugs to. Drug
resistance develops when you treat an organism with not
enough of the compound, so not enough drug is getting to
the bug. If you’re tucked away in a compartment within
the patient, where the drug isn’t going to get to, then you’re
already giving a sub-optimal dose of the drug. The com-
pounds that we use have to get over those barriers.
Diagnostics
TMcH
For many years we’ve used a smear test; that is, sputum
put onto a slide and then used to identify Mycobacter-
ium tuberculosis. This is a robust, simple tool, and has
served us well for over 100 years. However, it doesn’t
serve us well in the days when we need to understand
drug resistance in a quick and efficient way.
MCIL
The importance of diagnostics in the current era is that
we want to be able to make a diagnosis promptly. We’ve
got better and better at that. The introduction of mo-
lecular diagnostics such as GeneExpert have undoubt-
edly improved the sensitivity, and also the speed, of
diagnosis. What’s interesting about areas such as this,
is that you need both a very good test which, in gen-
eral terms, can be used close to the patient – so a
point-of-care test. However, you also need to re-
educate your healthcare workforce, and individuals
who are being tested, on the implications and value
of the test.
Treatment
MCIL
One of the big questions about treating TB is that, be-
cause the mycobacterium is both a slow-growing organ-
ism, and also because it is relatively hardy to being killed
by antimicrobials, it takes a long time to treat and effect-
ively cure TB. For example, the standard therapy to deal
with latent TB is 3 months of treatment, continuously.
The standard treatment for drug-sensitive active TB is
6 months of treatment. These are drugs that have poten-
tial toxicities. That in itself is a problem because, again,
if someone is feeling more unwell on the therapy, then
there’s a good chance that they may stop treatment.
PPJP
Unfortunately, we haven’t seen any improvement in the
treatment of drug-sensitive TB really for 30 or 40 years.
Whilst those were very effective trials and the regimen
works very well in trial settings – as we’ve seen in the
history of the TB epidemic, the regimen is inadequate to
control the disease. So we do need treatments; we need
better treatments, safer treatments, shorter treatments
that are easier for patients to take.
There have been a number of trials published in the
last 2 years looking at 4-month treatments. The idea be-
ing that a shorter, 4-month regimen would be easier to
take for patients and, if it could be shown to be as good
as the current standard of care, then that would greatly
improve outcomes in practice and make it easier for TB
programs to roll out treatment for a larger number of
patients. Unfortunately, those three large trials show
that none of the 4-month regimens being evaluated
were as good as the standard of care. So we’re still
looking for shorter treatments that can result in bet-
ter outcomes for TB.
A lot of the work in trials at the moment is looking at
how we can best identify the most promising regimens
to take forward to large expensive trials. So some of the
work that we’ve done, some of the research that’s being
presented in the BMC Medicine series, is looking at bet-
ter ways of doing clinical trials to identify those regi-
mens to take forward to large Phase III trials.
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Immune correlates
HF
At this particular time, immune correlates have emerged
as an important issue because we have begun, as a TB
community, to invest more in developing TB vaccines. If
you look pre-clinically, there’s now quite an exciting pipe-
line of vaccine candidates waiting to be moved into clin-
ical trials. What we don’t have at the moment is any real
way of assessing which of those pre-clinical candidates are
going to be the one that works and to go forward, because
we don’t have a correlate of immune protection.
Of course, we can’t invest in efficacy testing for every
one of those candidate TB vaccines. So we need tools –
we need biomarkers and immune correlates – to really se-
lect the most effective vaccines and to progress the clinical
development as quickly as we can. The reason we need to
do this is because – if we do want to end TB by 2035 –
we’re going need an effective vaccine by the year 2025.
Typically, we say it takes 10 years to develop a TB vac-
cine, so if we don’t start doing something about this today,
we’re not going to have that vaccine candidate by 2025.
WHO End TB Strategy
IA
The WHO has had, together with national TB programs,
great success in tackling the problem of TB. Over the
last cycle of international programs that contain TB, mil-
lions – tens of millions, over 40 million – lives are esti-
mated to have been saved. As a result of this success,
and building on it in relation to the United Nations Sus-
tainable Development Goals, the WHO has developed a
new strategy which is based on the vision that we want a
world that is rid of TB.
The strategy is based on three key pillars. These pillars
are important, including the need to have better inte-
grated patient-centred care, the need to have strengthen-
ing of programs and systems to support the delivery of
interventions, and better research and innovation. Re-
search and innovation is one area that those of us in uni-
versities have a key role to play and should contribute to
the discovery of new tools, so that we can achieve the
goals of the End TB Strategy by 2035.
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